Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,643 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a biomarker in locally advanced unresectable thymic epithelial neoplasm: A single-center, retrospective, longitudinal cohort study.
Kim DH, Lim Y, Kim S, Ock CY, Youk J, Kim M, Kim TM, Kim DW, Kim HJ, Koh J, Jung KC, Na KJ, Kang CH, Keam B. Kim DH, et al. Among authors: lim y. Thorac Cancer. 2023 Oct;14(30):3001-3011. doi: 10.1111/1759-7714.15089. Epub 2023 Sep 7. Thorac Cancer. 2023. PMID: 37675597 Free PMC article.
Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a predictive biomarker for axitinib in adenoid cystic carcinoma.
Kim DH, Lim Y, Ock CY, Park G, Park S, Song H, Ma M, Mostafavi M, Kang EJ, Ahn MJ, Lee KW, Kwon JH, Yang Y, Choi YH, Kim MK, Ji JH, Yun T, Kim SB, Keam B. Kim DH, et al. Among authors: lim y. Head Neck. 2023 Dec;45(12):3086-3095. doi: 10.1002/hed.27537. Epub 2023 Oct 13. Head Neck. 2023. PMID: 37828867 Clinical Trial.
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer.
Bang YH, Lee CK, Bang K, Kim HD, Kim KP, Jeong JH, Park I, Ryoo BY, Lee DK, Choi HJ, Chung T, Jeon SH, Shin EC, Oum C, Kim S, Lim Y, Park G, Ahn CH, Lee T, Finn RS, Ock CY, Shin J, Yoo C. Bang YH, et al. Among authors: lim y. Clin Cancer Res. 2024 Oct 15;30(20):4635-4643. doi: 10.1158/1078-0432.CCR-24-1265. Clin Cancer Res. 2024. PMID: 39150517
A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma.
Kim CG, Hong MH, Kim D, Lee BH, Kim H, Ock CY, Kelly G, Bang YJ, Kim G, Lee JE, Kim C, Kim SH, Hong HJ, Park YM, Sim NS, Park H, Park JW, Lee CG, Kim KH, Park G, Jung I, Han D, Kim JH, Cha J, Lee I, Kang M, Song H, Oum C, Kim S, Kim S, Lim Y, Kim-Schulze S, Merad M, Yoon SO, Kim HJ, Koh YW, Kim HR. Kim CG, et al. Among authors: lim y. Clin Cancer Res. 2024 May 15;30(10):2097-2110. doi: 10.1158/1078-0432.CCR-23-3249. Clin Cancer Res. 2024. PMID: 38457288 Clinical Trial.
7,643 results